23andMe Is Sinking Fast. Can the Company Survive?
SMRTR summary
23andMe, once valued at $6 billion, faces an uncertain future after a major data breach and declining sales. The genetic testing company has agreed to a $30 million lawsuit settlement, shuttered its drug discovery unit, and lost its board of directors, while its stock price has plummeted from $10 to under 50 cents per share.
SMRTR provides this summary for quick context. The original article belongs to Wired.
Read the original article